Thursday 16 October, 2025
Objectives: The aim of this observational study was to determine the population pharmacokinetic parameters of nevirapine, their variability, and to…
Read morePoster: Infection
Impacts of environmental, clinical and genetic factors on the response to vitamin D supplementation in HIV-positive patients
Thursday 16 October, 2025
Objectives: Vitamin D deficiency is highly prevalent in HIV-infected individuals and has been associated to the progression of the disease…
Read moreA Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients
Thursday 16 October, 2025
Objectives: Dolutegravir (DTG, S/GSK1349572) is an unboosted, once daily integrase inhibitor currently under development for the treatment of HIV infection….
Read moreMega-model of nevirapine population pharmacokinetics
Thursday 16 October, 2025
Objectives: To develop a mega-model, i.e. a model driven by raw data from multiple sources, of nevirapine (NVP) pharmacokinetics (PK)…
Read morePopulation Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV
Thursday 16 October, 2025
Objectives: Vicriviroc is a potent CCR5 antagonist for treating HIV-1 infection. This study aimed to (1) assess vicriviroc pharmacokinetic (PK)…
Read moreIn silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin
Thursday 16 October, 2025
Objectives: The developing problem of antibiotic resistance due to overuse of antibiotics is threatening public health. Valuable information on optimal…
Read morePKPD-modeling of time-kill curves from E. coli mutants exposed to ciprofloxacin
Thursday 16 October, 2025
Background: There is a need to better understand how antibiotics should be dosed to overcome and minimize development of resistance…
Read morePopulation pharmacokinetic model for protein binding and subcutaneous adipose tissue distribution of cefazolin in morbidly obese and non-obese patients
Thursday 16 October, 2025
Objectives: Morbidly obese patients are prone to surgical site infections. To reduce the risk of infection a prophylactic antibiotic agent…
Read morePopulation pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients
Thursday 16 October, 2025
Objectives: Morbidly obese patients are prone to surgical site infections. To reduce the risk of infection a prophylactic antibiotic agent…
Read moreCefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.
Thursday 16 October, 2025
Objectives: In this study we aimed to investigate the pharmacokinetics of cefazolin in morbidly obese patients undergoing weight reducing surgery….
Read more